Schedule a Vaccination | Reminder: Masks Are Still Required When Visiting
Director, Cincinnati Comprehensive Sickle Cell Center
Program Leader, Hematology and Gene Therapy Program
Marjory J. Johnson Chair, Gene and Cell Therapy
Professor, UC Department of Pediatrics
Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology
Punam Malik, MD, Omar Niss, MD4/15/2020
Punam Malik, MD6/27/2019
MBBS: University of Delhi, New Delhi, India, 1985.
MD: University of Delhi, New Delhi, India, 1989.
MS: University of Maryland, Baltimore, MD, 1991.
Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.
Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT.
Pediatric Blood and Cancer.
Cardiac pathophysiology in sickle cell disease.
Gbotosho, OT; Taylor, M; Malik, P.
Journal of Thrombosis and Thrombolysis.
Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development.
Cannon, P; Asokan, A; Czechowicz, A; Hammond, P; Kohn, DB; Lieber, A; Malik, P; Marks, P; Porteus, M; Verhoeyen, E; et al.
Human Gene Therapy.
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity.
Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al.
Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience.
Karkoska, KA; Todd, KE; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Niss, O; Quinn, CT; Ware, RE; McGann, PT.
Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels.
Shrestha, A; Chi, M; Wagner, K; Drake, A; Fulzele, K; Guichard, S; Malik, P.
Bone Marrow (BM) Delivery of Genetically-Modified (gm) Adult CD34+ Hematopoietic Stem and Progenitor Cells (HSPC) Improves Homing and Engraftment of Short-Term Progenitors over Long-Term Repopulating Hematopoietic Stem Cells.
Felker, S; Shrestha, A; Malik, P.
Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.
Niss, O; Lane, A; Asnani, MR; Yee, ME; Raj, A; Creary, S; Fitzhugh, C; Bodas, P; Saraf, SL; Sarnaik, S; et al.
Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis.
Hetzel, M; Lopez-Rodriguez, E; Mucci, A; Ha Nguyen, AH; Suzuki, T; Shima, K; Buchegger, T; Dettmer, S; Rodt, T; Bankstahl, JP; et al.
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.
Farrell, AT; Panepinto, J; Desai, AA; Kassim, AA; Lebensburger, J; Walters, MC; Bauer, DE; Blaylark, RM; DiMichele, DM; Gladwin, MT; et al.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2021 Cincinnati Children's Hospital Medical Center. All rights reserved.